G1 Therapeutics Profit Margin

G1 Therapeutics (GTHX) currently reports a profit margin of -76.93% as of June 2024. That compares with -92.8% in the prior-year period — up 17.1% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore G1 Therapeutics's profit margin history and peer comparisons.

G1 Therapeutics's profit margin increased from -92.8% to -76.93% — a 17.1% year-over-year increase (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

G1 Therapeutics's profit margin of -76.93% is lower than the Healthcare sector average of 13.89%. That is roughly 653.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but G1 Therapeutics's current -76.93% should be judged against Healthcare norms (sector average: 13.89%) and against GTHX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -76.93%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for G1 Therapeutics, and consider following GTHX for alerts when major investors trade the stock.